Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Lokness who wrote (1464)	12/4/2007 5:36:30 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 1494

First, they virtually bought the company for the cash paid for the new shares. You could say valuation was not terribly challenging and showing a return on it ought not to be so challenging either. A "partnership"--more likely on option-- with $50m upfront however would do it. Second, everyone with skin it this game with this crowd in this stadium is expert at finding new shareholders to take the place of old ones. Third, I don't even think they'll know whether v is a clinical, much less a commercial, success in 8 months. Make that 12 months! And we know it can do harm, so there is safety risk between now and topline data. For these reasons, I don't think BVF and GPP are going to leave their $60m on the table until P3 proves a subset analysis in stroke patients. This is my only point...and its just speculation on my part.